FC
LEGN icon

Financial Consulate’s Legend Biotech LEGN Stock Holding History

Financial Consulate’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94K Buy
171
+75
+78% +$2.02K ﹤0.01% 855
2026
Q1 		$1.74K Buy
+96
New +$1.83K ﹤0.01% 1005

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Financial Consulate's LEGN Position: Q2 2026 in Review

Financial Consulate increased its Legend Biotech (LEGN) stake by 78% in Q2 2026, buying an estimated $2.02K and bringing the position to 171 shares worth $4.94K. The position accounts for ﹤0.01% of the portfolio, ranked #855.

Financial Consulate first reported a position in LEGN in Q1 2026 and has held it in 2 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Financial Consulate held 171 shares of Legend Biotech worth $4.94K as of Q2 2026.
  • Financial Consulate bought 75 Legend Biotech shares in Q2 2026, an estimated $2.02K.
  • Legend Biotech made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #855 holding.
  • Financial Consulate first reported a position in Legend Biotech in Q1 2026 and has held it in 2 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.